We investigated the effects of ARI treatment on the phosphatidylinositol 3-kinase (PI3K)/AKT-ERK1/2 survival pathway, pivotal for maintaining CRC cell proliferation and invasion [31]. This evidence concerns the gene AKT1 and colorectal carcinoma.